

manner which promotes active immunization of the individual so as to build up a critical T cell response.--

--19(new). A pharmaceutical composition according to claim 16 wherein the agent is T cells which have been activated by poly-Glu,Tyr.--

A
cont.
--20(new). A pharmaceutical composition according to claim 19, wherein said poly-Glu,Tyr-specific activated T cells are autologous T cells, or allogeneic T cells from related donors, or HLA-matched or partially matched, semi-allogeneic or fully allogeneic donors.--

--21(new). A pharmaceutical composition according to claim 20, wherein said T cells are autologous T cells.--

--22(new). A pharmaceutical composition according to claim 21, wherein said autologous or semi-allogeneic T cells are derived from stored T cells.--

--23(new). A pharmaceutical composition according to claim 20, wherein said T cells are semi-allogeneic T cells.--

--24(new). A pharmaceutical composition according to claim 23, wherein said autologous or semi-allogeneic T cells are derived from stored T cells.--

--25(new). A pharmaceutical composition according to claim 16 for preventing or inhibiting neuronal degeneration in the central nervous system (CNS) or peripheral nervous system (PNS), for promoting nerve regeneration in the CNS or PNS, or for protecting CNS or PNS cells from glutamate toxicity.--

--26(new). A pharmaceutical composition according to claim 25, for treating an injury, disorder or disease of the CNS or PNS in order to prevent or inhibit neuronal degeneration or for promoting nerve regeneration, or for treating an injury, disorder or disease in the CNS or PNS caused or exacerbated by glutamate toxicity.--

cont. --27(new). A pharmaceutical composition according to claim 26, wherein said injury, disorder or disease is spinal cord injury, blunt trauma, penetrating trauma, brain coup or contrecoup, hemorrhagic stroke, or ischemic stroke.--

--28(new). A pharmaceutical composition according to claim 26, wherein said injury is spinal cord injury.--

--29 (new). A pharmaceutical composition according to claim 26, wherein said injury, disorder or disease is a senile dementia including Alzheimer's disease, Parkinsonian syndrome including Parkinson's disease, facial nerve (Bell's) palsy, Huntington's chorea, a motor neuron disease including amyotrophic lateral sclerosis, a prion disease including Creutzfeldt-Jakob disease, Alper's disease, Batten disease, Cockayne syndrome, Lewy body disease, status epilepticus, carpal tunnel syndrome, intervertebral disc herniation, vitamin deficiency, epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, opiate tolerance and dependence, an autoimmune disease, or a peripheral neuropathy associated with a disease such as amyloid polyneuropathy, diabetic neuropathy, uremic neuropathy, porphyric

A¹
and polyneuropathy, hypoglycemia, Sjogren-Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, IgA and IgG gammopathies, complications of various drugs such as nitrofurantoin, metronidazole, isoniazid and toxins such as alcohol or organophosphates, Charcot-Marie-Tooth disease, ataxia telangiectasia, Friedreich's ataxia, adrenomyeloneuropathy, giant axonal neuropathy, Refsum's disease, Fabry's disease, or lipoproteinemia.--

--30(new). A pharmaceutical composition according to claim 26, wherein said injury, disorder or disease is associated with the eye and includes non-arteritic optic neuropathy, age-related macular degeneration, a retinal disorder such as retinal degeneration or a disease associated with abnormally elevated intraocular pressure.--

--31(new). A pharmaceutical composition according to claim 30, wherein said disease associated with abnormally elevated intraocular pressure is glaucoma.--
